MedTrace Logo

LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients

NCT02895854 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-02-18

No results posted yet for this study

Summary

The aim of this trial is to find out if there are any differences in the profiles of acute and late adverse effects among men with low and intermediate risk prostate cancer treated either with low dose-rate brachytherapy or hypofractionated external radiotherapy (CyberKnife). Also the prostate specific antigen (PSA) responses and cost utility of each treatment will be analysed.

Conditions

Interventions

RADIATION

Hypofractionated RT 5 x 7,25 Gy

RADIATION

LDR-brachytherapy with I125 seeds

Sponsors & Collaborators

  • Kuopio University Hospital

    lead OTHER

Principal Investigators

  • Kristiina Vuolukka, MD · Cancer Center, KUH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-08
Primary Completion
2018-12-20
Completion
2021-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02895854 on ClinicalTrials.gov